Recital 29, Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 Decembe…

In forcecited 1×

Under Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products [OJ L 18, 22.1.2000, p. 1.], medicinal products designated as orphan medicinal products gain ten years of market exclusivity on the granting of a marketing authorisation for the orphan indication. As such products are frequently not patent-protected, the reward of supplementary protection certificate extension cannot be applied; when they are patent-protected, such an extension would provide a double incentive. Therefore, for orphan medicinal products, instead of an extension of the supplementary protection certificate, the ten-year period of orphan market exclusivity should be extended to twelve years if the requirement for data on use in the paediatric population is fully met.

  • Order of the General Court (Eighth Chamber), 3 September 2014. Shire Pharmaceutical Contracts Ltd v European Commission.Decision

    First, it should be noted that the letter of 2 September 2013 is a response to the applicant’s earlier letter to the Commission of 1 August 2013. In its letter, the applicant simply requested a meeting with the Commission in order to …

    3 Sep 2014 · 62013TO0583